RG6312 / Roche - LARVOL DELTA

Phase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration. (PubMed, Ophthalmol Sci) - P1a | "Further work is needed to evaluate the relevance of the IL-33/ST2 pathway in the pathophysiology of AMD. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • P1 data • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • CCL2 • CXCL10 • ICAM1 • IL33 • IL6

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - P1a | N=37 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed | N=63 ➔ 37

Enrollment change • Trial completion • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy (clinicaltrials.gov) - P1a | N=63 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy (clinicaltrials.gov) - P1a | N=63 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Feb 2022 ➔ Jan 2023 | Trial primary completion date: Feb 2022 ➔ Jan 2023

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy (clinicaltrials.gov) - P1a; N=63; Recruiting; Sponsor: Hoffmann-La Roche; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy (clinicaltrials.gov) - P1a; N=63; Recruiting; Sponsor: Hoffmann-La Roche

Clinical • New P1 trial • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration